MétaCan
Menu
Back to cohort

Positron Emission Tomography/Computed Tomography (PET/CT) and Radioimmunotherapy of Head and Neck Cancer Patient Derived Xenografts in NRG Mice with Theranostic [ <sup>64</sup> Cu]Cu-DOTA-Panitumumab F(ab′) <sub>2</sub> and [ <sup>177</sup> Lu]Lu-DOTA-Panitumumab F(ab′) <sub>2</sub>

2025· article· en· W4415381207 on OpenAlexafffund
Meysam Khosravifarsani, Conrad Chan, Anthony Ku, Noor Al‐saden, Jalna Meens, Laurie Ailles, Scott V. Bratman, Raymond M. Reilly

Bibliographic record

VenueMolecular Pharmaceutics · 2025
Typearticle
Languageen
FieldMedicine
TopicRadiopharmaceutical Chemistry and Applications
Canadian institutionsPrincess Margaret Cancer CentreUniversity Health NetworkUniversity of Toronto
FundersLeslie Dan Faculty of Pharmacy, University of TorontoCanadian Institutes of Health ResearchUniversity of Toronto
KeywordsRadioimmunotherapyEpidermal growth factor receptorPositron emission tomographyLymph nodeHead and neck squamous-cell carcinomaHead and neck cancerLung cancerMetastasisRadiation therapy

Abstract

fetched live from OpenAlex

Head and neck squamous cell carcinoma (HNSCC) expresses epidermal growth factor receptors (EGFR) in 90% of cases. Here we studied PET/CT imaging of three clinically relevant HNSCC patient derived xenografts (PDX) with low (#61531), moderate (#73191) or high (#88955) EGFR expression in NRG mice using anti-EGFR [ 64 Cu]Cu-DOTA-panitumumab F(ab′) 2 . We further assessed the effectiveness of β-particle-emitting [ 177 Lu]Lu-DOTA-panitumumab F(ab′) 2 for radioimmunotherapy (RIT) of these PDX. All PDX were visualized by PET/CT at 24 h postinjection (p.i.) of [ 64 Cu]Cu-DOTA-panitumumab F(ab’) 2 . In addition, in mice with PDX #88955, an axillary lymph node metastasis was imaged by PET and lung metastases were imaged by SPECT/CT at 3 to 12 d p.i. of [ 177 Lu]Lu-DOTA-panitumumab F(ab′) 2 . Tumor uptake of [ 64 Cu]Cu-DOTA-panitumumab F(ab′) 2 at 24 h p.i. was directly correlated with EGFR expression (6.7 ± 3.5%, 13.5 ± 2.5% and 16.7 ± 1.0% ID/g for PDX #61531, #73191 and #88955, respectively). Intravenous administration of 5.0 MBq (50 μg) of [ 177 Lu]Lu-DOTA-panitumumab F(ab′) 2 to healthy NRG mice caused no hematologic, liver or kidney toxicity or decrease in body weight. RIT with 4.0–5.0 MBq (50 μg) of [ 177 Lu]Lu-DOTA-panitumumab F(ab′) 2 decreased the tumor growth rate vs 0.9% NaCl by 2, 9 and 3.2-fold, respectively in mice with PDX #61531, #73191 and #88955 ( P = 0.014, P < 0.001, P = 0.004). Treatment of mice with unlabeled DOTA-panitumumab F(ab′) 2 did not decrease the tumor growth rate of PDX#61531 ( P = 0.457) but modestly decreased the tumor growth rate of PDX #73191 by 1.3-fold ( P = 0.024) and PDX #88955 by 1.4-fold ( P = 0.027). RIT was EGFR-specific as irrelevant anti-HER2 [ 177 Lu]Lu-DOTA-trastuzumab F(ab′) 2 was not effective for treatment of PDX #73191 vs 0.9% NaCl ( P = 0.282). RIT with [ 177 Lu]Lu-DOTA-panitumumab F(ab′) 2 was 3-fold more effective for treating moderately EGFR-expressing PDX #73191 than PDX #88955 with high EGFR expression. This may be explained by the human papilloma virus (HPV) positivity of PDX #73191 since HPV-positive HNSCC is more responsive to external radiation beam treatment. We conclude that [ 64 Cu]Cu-DOTA-panitumumab F(ab′) 2 and [ 177 Lu]Lu-DOTA-panitumumab F(ab′) 2 are a promising theranostic pair for PET/CT imaging and RIT of HNSCC.

Fetched live from OpenAlex and de-inverted. Abstracts are not stored in this database: the inverted indexes are 8.6 GB of the frame’s 9.3 GB of text, and the host has 13 GB free.

How this classification was reachedexpand

Full frame distilled prediction

Teacher imitation

Not calibrated prevalence, not ground truth. Human validation pending. Learned from the 10,348 direct Codex labels and 10,348 direct Gemma labels. Candidate is the union of thresholded teacher heads; consensus is their intersection. These outputs are machine_predicted_unvalidated and are not human labels or direct frontier model labels.

metaresearch head score (Codex)0.000
metaresearch head score (Gemma)0.000
Version: codex-gemma-dda1882f352aValidation status: machine_predicted_unvalidated
Candidate categoriesMeta-epidemiology (narrow)
Consensus categoriesnone
DomainCandidate signal: none · Consensus signal: none
Study designCandidate signal: Bench or experimental · Consensus signal: Bench or experimental
GenreCandidate signal: Empirical · Consensus signal: Empirical
Teacher disagreement score0.026
Threshold uncertainty score0.999

Codex and Gemma teacher scores by category

CategoryCodexGemma
Metaresearch0.0000.000
Meta-epidemiology (narrow)0.0010.001
Meta-epidemiology (broad)0.0010.000
Bibliometrics0.0010.002
Science and technology studies0.0000.001
Scholarly communication0.0000.000
Open science0.0000.000
Research integrity0.0000.001
Insufficient payload (model declined to judge)0.0000.000

Machine scores (provisional)

The two teacher heads of the student model, read on this work. A score orders the frame for review; it never asserts a category, and the validation status ships verbatim with every row.

Baseline scores from an immature model (maturity gate not passed, 7 training rounds). Scores rank; they never assert a category.

Opus teacher head0.010
GPT teacher head0.276
Teacher spread0.265 · how far apart the two teachers sit on this one work
Validation statusscore_only:v0-immature-baseline · verbatim from the scoring run: score_only means the number may rank works, and no category label ships from it

Classification

machine, unvalidated

Machine predicted; a candidate call from one teacher head, not a consensus.

Study designBench or experimental
Domainnot available
GenreEmpirical

How this classification was reached, model by model and score by score, is at the end of the page under "How this classification was reached".

Quick stats

Citations1
Published2025
Admission routes2
Has abstractyes

Explore more

Same venueMolecular PharmaceuticsSame topicRadiopharmaceutical Chemistry and ApplicationsFrench-language works237,207